Skip to main content
SpringerLink
Log in

Metrics and Outcomes of Systemic Lupus Erythematosus in Clinical Practice

  • Chapter
  • First Online:
Outcome Measures and Metrics in Systemic Lupus Erythematosus

  • 501 Accesses

Abstract

This chapter explores advantages and disadvantages of using outcome metrics to clinically monitor patients with systemic lupus erythematosus (SLE) in clinical practice. Advantages include regular objective assessments of disease activity and damage along with prognostic assessments of morbidity and mortality. Disadvantages include administrative burden and the time commitment necessary to carry out the instruments. We also review current guidelines that recommend patient assessments using validated instruments of disease activity and validated disease damage metrics. We also provide an overview of several validated disease activity and damage metrics including the SLEDAI, SLAM, SLE-DAS, and BILAG.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Keeling SO, Vandermeer B, Medina J, Chatterley T, Nevskaya T, Pope J, et al. Measuring disease activity and damage with validated metrics: a systematic review on mortality and damage in systemic lupus erythematosus. J Rheumatol. 2018;45(10):1448–61.

    Article  PubMed  Google Scholar 

  2. Nuttall A, Isenberg DA. Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: new aspects. Best Pract Res Clin Rheumatol. 2013;27(3):309–18.

    Article  PubMed  Google Scholar 

  3. Keeling SO, Bissonauth A, Bernatsky S, Vandermeer B, Fortin PR, Gladman DD, et al. Practice variations in the diagnosis, monitoring, and treatment of systemic lupus erythematosus in Canada. J Rheumatol. 2018;45(10):1440–7.

    Article  PubMed  Google Scholar 

  4. Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther. 2015;17:183.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, et al. Canadian Rheumatology Association recommendations for the assessment and monitoring of systemic lupus erythematosus. J Rheumatol. 2018;45(10):1426–39.

    Article  PubMed  Google Scholar 

  6. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–45.

    Article  CAS  PubMed  Google Scholar 

  7. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630–40.

    Article  CAS  PubMed  Google Scholar 

  8. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–91.

    PubMed  Google Scholar 

  9. Touma Z, Urowitz MB, Ibañez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus. 2011;20(1):67–70.

    Article  CAS  PubMed  Google Scholar 

  10. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550–8.

    Article  CAS  PubMed  Google Scholar 

  11. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142(12 Pt 1):953–62.

    Article  CAS  PubMed  Google Scholar 

  12. Touma Z, Gladman DD, Ibañez D, Urowitz MB. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol. 2011;38(2):275–84.

    Article  PubMed  Google Scholar 

  13. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989;32(9):1107–18.

    Article  CAS  PubMed  Google Scholar 

  14. Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus. 2001;10(6):405–9.

    Article  CAS  PubMed  Google Scholar 

  15. Jesus D, Matos A, Henriques C, Zen M, Larosa M, Iaccarino L, et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis. 2019;78(3):365–71.

    Article  CAS  PubMed  Google Scholar 

  16. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86(7):447–58.

    CAS  PubMed  Google Scholar 

  17. Yee CS, Cresswell L, Farewell V, Rahman A, Teh LS, Griffiths B, et al. Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford). 2010;49(9):1665–9.

    Article  Google Scholar 

  18. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125(5):889–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Thanou A, Chakravarty E, James JA, Merrill JT. Which outcome measures in SLE clinical trials best reflect medical judgment? Lupus Sci Med. 2014;1(1):e000005.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363–9.

    Article  CAS  PubMed  Google Scholar 

  22. Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum. 2012;64(12):4021–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Yazdany J, Trupin L, Gansky SA, Dall'era M, Yelin EH, Criswell LA, et al. Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011;63(8):1170–7.

    Article  Google Scholar 

  24. Katz P, Trupin L, Rush S, Yazdany J. Longitudinal validation of the Brief Index of Lupus Damage. Arthritis Care Res (Hoboken). 2014;66(7):1057–62.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Ambika Gupta

  2. Division of Rheumatology, Department of Medicine, University of Western Ontario, London, ON, Canada

    Janet Pope

  3. Centre for Prognosis in Rheumatic Disease, Toronto Lupus Clinic, Division of Rheumatology, Department of Medicine, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada

    Zahi Touma

  4. Division of Rheumatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada

    Stephanie Keeling

Authors
  1. Ambika Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janet Pope
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zahi Touma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephanie Keeling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ambika Gupta .

Editor information

Editors and Affiliations

  1. Medicine, University of Toronto, Toronto, ON, Canada

    Zahi Touma

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gupta, A., Pope, J., Touma, Z., Keeling, S. (2021). Metrics and Outcomes of Systemic Lupus Erythematosus in Clinical Practice. In: Touma, Z. (eds) Outcome Measures and Metrics in Systemic Lupus Erythematosus. Springer, Cham. https://doi.org/10.1007/978-3-030-73303-2_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-73303-2_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-73302-5

  • Online ISBN: 978-3-030-73303-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation